This company has been marked as potentially delisted and may not be actively trading. Gemphire Therapeutics (GEMP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock GEMP vs. XLO, VRCA, SPRO, CNTB, RFL, ATNM, ANEB, AADI, RNTX, and APLTShould you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Xilio Therapeutics (XLO), Verrica Pharmaceuticals (VRCA), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Rafael (RFL), Actinium Pharmaceuticals (ATNM), Anebulo Pharmaceuticals (ANEB), Aadi Bioscience (AADI), Rein Therapeutics (RNTX), and Applied Therapeutics (APLT). These companies are all part of the "medical" sector. Gemphire Therapeutics vs. Xilio Therapeutics Verrica Pharmaceuticals Spero Therapeutics Connect Biopharma Rafael Actinium Pharmaceuticals Anebulo Pharmaceuticals Aadi Bioscience Rein Therapeutics Applied Therapeutics Xilio Therapeutics (NASDAQ:XLO) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation. Do analysts prefer XLO or GEMP? Xilio Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 382.80%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Gemphire Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemphire Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor XLO or GEMP? In the previous week, Xilio Therapeutics had 2 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Gemphire Therapeutics. Xilio Therapeutics' average media sentiment score of 0.04 beat Gemphire Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Xilio Therapeutics Neutral Gemphire Therapeutics Neutral Do insiders & institutionals have more ownership in XLO or GEMP? 54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation and earnings, XLO or GEMP? Gemphire Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$6.34M6.76-$76.40M-$1.28-0.65Gemphire TherapeuticsN/AN/A-$23.64MN/AN/A Which has more risk & volatility, XLO or GEMP? Xilio Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500. Does the MarketBeat Community prefer XLO or GEMP? Gemphire Therapeutics received 277 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 69.98% of users gave Gemphire Therapeutics an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Gemphire TherapeuticsOutperform Votes28969.98% Underperform Votes12430.02% Is XLO or GEMP more profitable? Xilio Therapeutics' return on equity of -211.50% beat Gemphire Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Gemphire Therapeutics N/A -419.70%-173.05% SummaryXilio Therapeutics beats Gemphire Therapeutics on 10 of the 14 factors compared between the two stocks. Get Gemphire Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GEMP vs. The Competition Export to ExcelMetricGemphire TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.23M$6.70B$5.47B$7.82BDividend YieldN/A3.17%5.43%4.30%P/E RatioN/A7.2022.3718.43Price / SalesN/A239.17391.12101.46Price / CashN/A65.8538.1834.62Price / Book1.526.306.684.19Net Income-$23.64M$142.95M$3.22B$248.05M Gemphire Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GEMPGemphire TherapeuticsN/A$0.82-3.2%N/A-72.2%$12.23MN/A0.009Gap DownXLOXilio Therapeutics3.0755 of 5 stars$0.84+2.9%$4.00+376.8%-18.0%$43.44M$6.34M-0.4970VRCAVerrica Pharmaceuticals3.8931 of 5 stars$0.47+0.1%$9.50+1,938.6%-92.6%$42.59M$7.57M-0.2540Positive NewsSPROSpero Therapeutics4.4724 of 5 stars$0.75+3.7%$5.00+564.9%-49.3%$42.04M$27.40M10.74150Short Interest ↑Positive NewsCNTBConnect Biopharma2.6408 of 5 stars$0.75flat$8.00+973.8%-42.1%$40.24M$24.12M0.00110Short Interest ↑Gap UpRFLRafael0.8745 of 5 stars$1.60-5.1%N/A+2.4%$39.96M$706,000.00-0.9620Short Interest ↓ATNMActinium Pharmaceuticals1.3917 of 5 stars$1.28+6.3%$7.40+480.4%N/A$39.78M$81,000.00-0.9230Gap DownANEBAnebulo Pharmaceuticals2.3383 of 5 stars$1.01-0.5%$8.00+696.0%-59.2%$39.03MN/A-3.394Short Interest ↑Positive NewsGap UpAADIAadi BioscienceN/A$1.57+1.9%$1.67+6.2%-10.1%$38.77M$25.07M-0.6940Gap UpRNTXRein TherapeuticsN/A$1.76-1.0%N/AN/A$38.77MN/A-0.579Analyst RevisionGap DownAPLTApplied Therapeutics4.0759 of 5 stars$0.33-1.4%$6.10+1,759.8%-90.6%$38.05M$455,000.00-0.2030Positive News Related Companies and Tools Related Companies Xilio Therapeutics Competitors Verrica Pharmaceuticals Competitors Spero Therapeutics Competitors Connect Biopharma Competitors Rafael Competitors Actinium Pharmaceuticals Competitors Anebulo Pharmaceuticals Competitors Aadi Bioscience Competitors Rein Therapeutics Competitors Applied Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GEMP) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GEMP Stock Free GEMP Stock Alerts